Pharmaceutical Technology Europe, August 2012 Issue (PDF)

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

The reduction is expected to be “substantially completed,” the San Diego-based company said, in the second quarter of 2025.

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments.